Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease
暂无分享,去创建一个
M. Emoto | M. Inaba | S. Okuno | T. Yamakawa | E. Ishimura | S. Shoji | D. Kabata | K. Mori | A. Tsuda | Hideki Uedono | S. Nakatani | Fumiyuki Morioka | Kozo Nishide | Yuri Machiba
[1] Mark T Mills,et al. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis , 2020, BMJ Open.
[2] D. Mekahli,et al. Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells , 2018, Scientific Reports.
[3] Y. Mu,et al. Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis , 2018, Scientific Reports.
[4] R. Hays,et al. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[6] R. Gansevoort,et al. Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease , 2017, The New England journal of medicine.
[7] Y. Ubara,et al. Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] D. Wheeler,et al. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) , 2017, Kidney international supplements.
[9] C. Ahn,et al. Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease , 2017, BMC Nephrology.
[10] G. Valenti,et al. Localization and function of the renal calcium-sensing receptor , 2016, Nature Reviews Nephrology.
[11] F. Cosio,et al. Volume regression of native polycystic kidneys after renal transplantation. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] Hyo Sang Kim,et al. Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease , 2015, PloS one.
[13] I. Narita,et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial , 2015, Clinical and Experimental Nephrology.
[14] C. Wanner,et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. , 2014, Kidney international.
[15] Ajay V. Srivastava,et al. Autosomal dominant polycystic kidney disease. , 2014, American family physician.
[16] K. Hata,et al. Clinical Experiences of Bixalomer Usage at Our Hospital , 2014, Therapeutic apheresis and dialysis.
[17] H. Fujiki,et al. Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[18] R. Roepman,et al. Polycystic liver disease: ductal plate malformation and the primary cilium. , 2014, Trends in molecular medicine.
[19] V. Torres,et al. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. , 2014, Journal of the American Society of Nephrology : JASN.
[20] B. Leibovich,et al. A simple method to estimate renal volume from computed tomography. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[21] H. Jüppner,et al. Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH , 2013, Proceedings of the National Academy of Sciences.
[22] Eiji Higashihara,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.
[23] Vladimir G. Gainullin,et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. , 2012, The Journal of clinical investigation.
[24] Douglas K. Atchison,et al. Parathyroid hormone stimulates juxtaglomerular cell cAMP accumulation without stimulating renin release. , 2012, American journal of physiology. Renal physiology.
[25] F. Rybicki,et al. Comprehensive Comparative Study of Computed Tomography–Based Estimates of Split Renal Function for Potential Renal Donors: Modified Ellipsoid Method and Other CT-Based Methods , 2012, Journal of computer assisted tomography.
[26] D. Cusi,et al. Calcium-sensing receptor and calcium kidney stones , 2011, Journal of Translational Medicine.
[27] D. Wallace,et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. , 2011, American journal of physiology. Renal physiology.
[28] V. Gattone,et al. Calcimimetics inhibit renal pathology in rodent nephronophthisis. , 2011, Kidney international.
[29] A. Chapman,et al. Imaging approaches to patients with polycystic kidney disease. , 2011, Seminars in nephrology.
[30] M. F. Seifert,et al. Calcimimetic inhibits late-stage cyst growth in ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.
[31] S. Somlo,et al. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] CaCO,et al. Clinical Practice Guideline for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[33] J. Grantham,et al. Clinical practice. Autosomal dominant polycystic kidney disease. , 2008, The New England journal of medicine.
[34] F. Dekker,et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[35] A. Takakura,et al. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1. , 2008, Kidney international.
[36] M. Inaba,et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. , 2007, Journal of the American Society of Nephrology : JASN.
[37] Yves Pirson,et al. Autosomal dominant polycystic kidney disease , 1992, The Lancet.
[38] Laurie A. Smith,et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. , 2006, Journal of the American Society of Nephrology : JASN.
[39] T. Ikizler,et al. Uremic malnutrition is a predictor of death independent of inflammatory status. , 2004, Kidney international.
[40] K. Jain,et al. Normal organ volume assessment from abdominal CT , 2004, Abdominal Imaging.
[41] Vincent H Gattone,et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.
[42] Y. Ubara,et al. Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] G. Hendy,et al. Extracellular Calcium-sensing Receptor Is Expressed in Rat Hepatocytes , 2001, The Journal of Biological Chemistry.
[44] E. Brown,et al. Extracellular calcium sensing and extracellular calcium signaling. , 2001, Physiological reviews.
[45] M F Balandrin,et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] E. Brown,et al. Localization of the extracellular Ca2+/polyvalent cation-sensing protein in rat kidney. , 1998, American journal of physiology. Renal physiology.
[47] S. Nagao,et al. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[48] I. Ishikawa,et al. Volume changes in autosomal dominant polycystic kidneys after the initiation of hemodialysis. , 1993, Nephron.